This is a Provisional Conference Programme.

For further information on this event please contact us.

Registration, Posters Set-Up & Opening Remarks


Moderator: To be confirmed

‘Pushing the envelope of HIV-1 vaccine design’

Richard Wyatt
(Scripps Research Institute, La Jolla, California, USA)

‘Conventional and unconventional VLP based strategies for development of HIV vaccines’

Bryce Chackerian1, Alemu Mogus1, Julianne Peabody1, Larance Ronsard3, David Peabody1, Moriya Tsuji2 and Daniel Lingwood3
(1 University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; 2 Aaron Diamond AIDS Research Center, New York, USA; 3 The Ragon Institute of MGH, MIT, and Harvard, Cambridge, Massachusetts, USA)

‘A next generation Alzheimers vaccine’

Martin Bachmann
(University of Bern, Bern, Switzerland)

Lunch Break & Posters


Moderator: To be confirmed

‘VLPs of ssRNA phages: Diversity, strucure and applications in vaccine development’
Kaspars Tars
(University of Latvia, Riga, Latvia)

‘Design of hepatitis B virus-like particles (VLPs) to optimise immunisation outcomes for preventative or therapeutic applications’
Hans Netter
(Peter Doherty Institute, Melbourne, Victoria, Australia)

‘A strategy for the design of genetically thermo-stabilised, immunogenic poliovirus empty capsids for use as VLP vaccines’
Helen Fox, Sarah Knowlson, Philip Minor and Andrew J. Macadam
(Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK)

Tea Break & Posters


Moderator: To be confirmed

‘VLP-based vaccines for cardiovascular disease’
Alexandra Fowler1, Erin Crossey1, Maureen Sampson2, Marcelo Amar2, John Schiller3, Koen Van Rompay4, Alan Remaley2 and Bryce Chackerian1
(1 University of New Mexico School of Medicine, Albuquerque, New Mexico, USA; 2 NIH/NHLBI, Bethesda, Maryland, USA; 3 NIH/NCI, Bethesda, Maryland, USA; 4 California Regional Primate Center, Davis, California, USA)

‘Liposome-adjuvanted Self-Assembling Protein Nanoparticles (SAPN) for HIV-1 Vaccine Development’
Zoltan Beck 
(US Military HIV Research Program (MHRP), Laboratory of Antigen and Adjuvant Research, Walter Reed Army Institute of Research (WRAIR), Silver Spring, Maryland, USA)

‘Exploiting Pichia pastoris for production of a VLP vaccine against poliomyelitis’
Lee Sherry1, Keith Grehan1, Helen Fox2, Mohammad W. Bahar3, Elizabeth E. Fry3, David I. Stuart3, Andrew J. Macadam2, David J. Rowlands1
and Nicola J. Stonehouse1
(1 School of Molecular and Cellular Biology, University of Leeds, Leeds, UK; 2 Division of Virology, National Institute for Biological Standards and Control, South Mimms, Potters Bar, UK; 3 Division of Structural Biology, University of Oxford, Oxford, UK)


Moderator: To be confirmed

‘Plant VLPs in vaccine development’
Andris Zeltins
(University of Latvia, Riga, Latvia)

‘Plant based norovirus VLPs: From molecule design to phase I clinical trials’
Franziska Jarczowski
(Icon Genetics GmbH, Halle (Saale), Germany)

‘The suitability of plants for the production of Dengue Virus-like particles’
Daniel Ponnorf1, Yulia Meshcheriakova1, Hadrien Peyret1 and George P. Lomonossoff1
(1 Department for Biological Chemistry, John Innes Centre, Norwich, UK; 2 Plant Bioscience Ltd., Norwich Research Park, Norwich, UK)

‘The efficacy of a plant-produced virus-like particle vaccine against H6 avian influenza in specific-pathogen-free chickens’
T. Smith1,2, M.M. O’Kennedy1,2, D.B.R. Wandrag1, M. Adeyemi1 and C. Abolnik1
(1 Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, South Africa; 2 NextGen Health, Council for Scientific and Industrial Research, Pretoria, South Africa)

Coffee Break & Posters


Moderator to be confirmed

‘Affinity-selection on the MS2 VLP platform as a means for producing molecular mimics of vaccine antigens’
David Peabody
(University of New Mexico, Albuquerque, New Mexico, USA)

‘Monoclonal antibody – equivalent performance of IL17 – targeting VLP-vaccines’
Alexandra Moleda, Andris Zeltins, Martin Bachman and John Foerster
(University of Dundee, Dundee, Scotland, UK)

‘Immunological characterization of GMMA-based vaccines’
O. Rossi, M.G. Aruta, F. Mancini, A. Acquaviva, F. Citiulo, A. Podda, L.B. Martin, F. Micoli and F. Necchi
(GSK Vaccines Institute for Global Health S.r.l. (GVGH), Siena, Italy)

Lunch Break & Posters


Moderator: To be confirmed

‘Adjuvanted virosome VLP as flexible and potent universal vaccine platform for induction of systemic and mucosal immunity’
Mario Amacker, Toon Stegmann, Ronald Kempers and Sylvain Fleury
(Mymetics SA, Epalinges, Switzerland and Mymetics B.V., Leiden, The Netherlands)

‘1918 influenza Virus-Like Particle Vaccine structural analysis by cryo-electron microscopy with implications for viral surface glycoprotein vaccines’
Audray K. Harris, Dustin M. McCraw, John R. Gallagher, Udana Torian, Mallory L. Myers, Michael T. Conlon and Neetu M. Gulati
(Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA)

‘Live vaccine based on probiotic Enterococcus L3 strain containing conservative epitopes of influenza virus neuraminidase’
Yulia Desheva
(Institute of Experimental Medicine, St. Petersburg, Russian Federation)

Tea Break & Posters


Moderator: To be confirmed

‘Exploration and development of a novel personalized breast-cancer vaccine based on virus-like particles by incorporating tumor-specific T-cell epitopes’
Mona O. Mohsen1, Monique Vogel1, Said Dermime2, Varghese Inchakalody2, Daniel Speiser3, Alexander Knuth2, Michal Bassani3 and Martin F. Bachmann1
(1 Department of BioMedical Research, Immunology RIA, University of Bern, Bern, Switzerland; 2Interim Translational Research Institute “iTRI”, National Center for Cancer Care & Research (NCCCR), Doha, State of Qatar; 3 Department of Oncology, University of Lausanne, Lausanne, Switzerland)

‘Bacteriophage virus-like particle vaccines for opioids’
Kathryn M. Frietze
(University of New Mexico School of Medicine, Albuquerque, New Mexico, USA)

‘Novel HBV S/preS1 chimeric antigen particles produced in mammalian cells and plants induce stronger immune response than the standard vaccine, S’
Mihaela-Olivia Dobrica1, Catalin Lazar1, Lisa Paruch2, Andre van Eerde2, Hege Steen2, Sissel Haugslien2, Catalin Tucureanu3, Iuliana Caras3, Sonya Ciulean3, Adrian Onu3, Crina Stavaru3, Alexandru Branzan4, Jihong Liu Clarke2 and Norica Nichita1
(1 Institute of Biochemistry of the Romanian Academy, Bucharest, Romania; 2 NIBIO – Norwegian Institute for Bioeconomy Research, Ås, Norway; 3 “Cantacuzino” National Research Institute, Bucharest, Romania; 4 Institute of Biology of the Romanian Academy, Bucharest, Romania)


Moderator to be confirmed

‘Self-emulsifying adjuvant systems (SE-AS) containing alpha-tocopherol show comparable immune responses to AS03’
Rushit N. Lodaya1, Mansoor M. Amiji2 and Derek T. O’Hagan1
(1 GSK, Slaoui Centre for Vaccines Research, Rockville, Maryland, USA; 2 Northeastern University, Department of Pharmaceutical Sciences, Boston, Massachusetts USA)

‘Bioengineering rabbit hemorrhagic disease virus capsid to generate a multivalent immune response against foreign B-cell epitopes’
María Zamora-Ceballos, Noelia Moreno, Jose R.Castón, Alí Alejo, Esther Blanco and Juan Bárcena
(Centro de Investigación en Sanidad Animal (CISA-INIA), Valdeolmos, Madrid, Spain)

‘VLP vaccine against influenza’
Anna Kirsteina
(University of Latvia, Riga, Latvia)

Coffee Break & Posters Breakdown


Moderator: To be confirmed

‘Nano-flow cytometry: A platform for comprehensive virus and extracellular vesicle analysis’
Dimitri Aubert
(NanoFCM, Medicity, Nottingham, UK)

Latebreaker abstracts for oral and poster presentation at VLPNPV 2022 are called for. Please see the Participation page for details.

‘Plug and Play platform technology for rapid response to emerging pathogens’
Mirriam Tacken1, Benjamin Gutjahr3, Paul Wichgers Schreur1, Lucien van Keulen1, Jet Kant1, Sandra van de Water1, Yanyin Lin1, Markus Keller3, Martin Groschup3, Martin Eiden3, Melanie Rissmann3, Felicitas von Arnim3, Rebecca König3, Alexander Brix4, Catherine Charreyre5, Jean-Christophe Audonnet5
and Jeroen Kortekaas1,2
(1 Department of Virology, Wageningen Bioveterinary Research, Lelystad, The Netherlands; 2Laboratory of Virology, Wageningen University and Research, Wageningen, The Netherlands; 3Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany; 4Boehringer Ingelheim, Hannover, Germany; 5 Boehringer Ingelheim, Lyon, France)

This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.